Clinical Neuroscience

[Prognostic factors of primary spinal tumors]

LAZÁRY Áron1, BORS István Béla1, SZÖVÉRFI Zsolt1, RÓNAI Márton1, VARGA Péter Pál1

MAY 30, 2012

Clinical Neuroscience - 2012;65(05-06)

[Aims - Primary spinal tumors are rare diseases and there are less objective data in the international literature. We analyzed the epidemiology and clinical consequences of primary spinal tumors based on the clinical experience of the National Center for Spinal Disorders. Methods - Demographic and clinical data of 300 patients treated in our institute between 1995 and 2007 was collected retrospectively and analysed. Results - Beyond the relatively more frequent pathologies (chordoma, myeloma multiplex) we treated in our hospital some of the very rare types of tumors (spinal leiomyosarcoma, synovial sarcoma). Primary spinal tumors are most often located in the lumbosacral region causing most frequently (73%) local or radiating pain. Modern therapy of these patologies is based on the surgical intervention. Mean operation time was 130 minutes, mean blood loss was 650 ml in our pratice during these often technically challenging surgeries. We found a significant association among the operation time, the blood loss and the extension of the tumor (p<0.01). Histology (p<0.0001), severity of symptomes (p<0.05) and blood loss (p<0.05) were significantly related to mortality. Local recurrence was more than 5-fold in case of patients previously operated in another institute (p<0.0001). Conclusions - We successfully determined some significant prognostic factor on clinical behavior of primary spinal tumors performing a large scale retrospective study. Long time follow up of the patients and completion of our database with prospective data are planned for the future.]

AFFILIATIONS

  1. Országos Gerincgyógyászati Központ, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[Effect of two month positive airway pressure therapy on the structure of sleep, cognitive function and anxiety]

CSÁBI Eszter, VÁRSZEGI Mária, SEFCSIK Tamás, NÉMETH Dezsõ

[Obstructive sleep apnea is a common disorder, characterized by repeated episodes of upper airway obstruction during sleep, resulting intermittent hypoxia and disruption of the normal sleep pattern, which caused cognitive dysfunction in these patients. Nasal continuous positive airway pressure is the treatment of choice for this disorder. The aim of the study is to evaluate the effect of short-term positive airway pressure on sleep pattern (polisomnographic measures), cognitive function and anxiety. Twenty four newly diagnosed and previously untreated patients with obstructive sleep apnea were evaluated a battery of neuropsychological tests before and after 2 and a half months of the treatment. We focused on working memory, short and long-term episodic memory, executive functions, anxiety and subjective sleepiness. Our results showed that the two and half month of treatment improved the respiration during sleep, sleep pattern and the subjective sleepiness. We found improvement in short- and long-term verbal memory, and complex working memory. Despite of treatment we did not find improvement in visuospatial learning. These results reveal that 2 and a half months of positive airway pressure treatment restored not only the normal respiration during sleep and normal sleep pattern, but also the cognitive functions. Our study suggests that cognitive dysfunction is at least partial reversible in obstructive sleep apnea patients after positive airway pressure treatment.]

Clinical Neuroscience

[Valutation of phasis III. FREEDOMS and TRANSFORMS studies, clinical and MRI results]

JAKAB Gábor

Clinical Neuroscience

[Letter]

GYURIS Jenő

Clinical Neuroscience

[Non-invasive brain stimulation for relieving acute and chronic pain]

CSIFCSÁK Gábor, ANTAL Andrea

[Controlling pain has always been one of the biggest challenges of medical science. Despite pharmacological developments, still many patients suffer from long-lasting pain. During the last 40 years several surgical interventions have been used to modulate the activity of the central nervous system in order to control chronic, pharmacoresistant pain. Because such interventions may involve very serious adverse events, safer and at least equally efficient methods are still required. In the 90’s new techniques of non-invasive brain stimulation have been introduced that enable the facilitation or inhibition of distinct cortical areas. These methods are based on the electrical stimulation of brain structures and to date they have been successfully used to modulate perceptual, cognitive and motor functions in healthy subjects and various diseases as well. In this review we describe such techniques of non-invasive brain stimulation, namely repeated transcranial magnetic stimulation and transcranial direct current stimulation and review the current literature about their efficacy in controlling acute and chronic pain.]

Clinical Neuroscience

[European treatment recommendation of neuromyelitis optica spectrum disorders: critical remarks and case discussion]

KÕSZEGI Edit, ILLÉS Zsolt

[Neuromyelitis optica is a demyelinating disease of the central nervous system mediated by antibodies against the waterchannel aquaporin4 (AQP4). In a number of cases the clinical manifestation is spatially limited. Such events of separate longitudinally extensive transverse myelitis (LETM) or relapsing/bilateral optic neuritis (RION/BON) are defined as NMO spectrum diseases. The diagnosis is further challenged by anti-AQP4 seronegative cases. While chronic immunosuppressive therapy should be introduced in definitive NMO, treatment strategy of the NMO spectrum is less defined. Recent EFNS guidelines recommend chronic immunosuppressive treatment of NMO spectrum diseases depending on the clinical course even in AQP4-seropositive cases. Presenting a case with relapsing optic neuritis, here we emphasize the importance of early immunosuppressive therapy in all seropositive NMO spectrum diseases regardless of relapse severity, in order to prevent an upcoming devastating relapse, i.e. NMO conversion.]

All articles in the issue

Related contents

Clinical Neuroscience

[Initial clinical experience with radio-frequency assisted percutaneous vertebral augmentation in the treatment of vertebral compression fractures]

MAROSFŐI Miklós, KULCSÁR Zsolt, BERENTEI Zsolt, GUBUCZ István, SZIKORA István

[Purpose - Percutaenous Vertebroplasty (PVP) is effective in alleviating pain and facilitating early mobilization following vertebral compression fractures. The relatively high risk of extravertebral leakage due to uncontrolled delivery of low viscosity bone cement is an inherent limitation of the technique. The aim of this research is to investigate the ability of controlled cement delivery in decreasing the rate of such complications by applying radiofrequency heating to regulate cement viscosity. Method and material - Thirty two vetebrae were treated in 28 patients as part of an Ethics Committee approved multicenter clinical trial using RadioFreqency assisted Percutaenous Vertebral Augmentation (RF-PVA) technique. This technique is injecting low viscosity polymethylmethacrylate (PMMA) bone cement using a pressure controlled hydraulic pump and applying radiofrequency heating to increase cement viscosity prior to entering the vertebral body. All patients were screened for any cement leakage by X-ray and CT scan. The intensity of pain was recorded on a Visual Analog Scale (VAS) and the level of physical activiy on the Oswestry Disability Index (ODI) prior to, one day, one month and three months following procedure. Results - All procedures were technically successful. There were no clinical complication, intraspinal or intraforaminal cement leakage. In nine cases (29%) a small amount of PMMA entered the intervertebral space through the broken end plate. Intensity of pain by VAS was reduced from a mean of 7.0 to 2.5 and physical inactivity dropped on the ODI from 52% to 23% three months following treatment. Conclusion - In this small series controlled cement injection using RF-PVA was capable of preventing clinically hazardous extravertebral cement leakage while achieving outcomes similar to that of conventional vertebroplasty.]

Clinical Neuroscience

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience

LUKÁCS Gábor, TÓTH Zoltán, SIPOS Dávid, CSIMA Melinda, HADJIEV Janaki, BAJZIK Gábor, CSELIK Zsolt, SEMJÉN Dávid, REPA Imre, KOVÁCS Árpád

Introduction - Glioblastoma multiforme (GBM) is the most common malignant primary anomaly of central nervous system. The GBM infiltrates the nearly sturctures from the initial tumor and its metastatic attribution is well known. The aim of our single-centered retrospective study was to introduce the importance of postoperative medical imaging confirmation of total tumor resection for patient with GBM combined concomitant and adjuvant chemoradiotherapy on a 10 year long patient follow up. Methods - From January 2006 to April 2015 we registered 59 patients with newly diagnosed GBM at the University of Kaposvár Health Center Institute of Diagnostic Imaging and Radiation Oncology. The histological diagnosis was confirmed by a proficient neuropathologist (World Health Organisation WHO; grade IV astrocytoma). According to histological status if the ECOG performance status of patients allowed it the mutidisciplinary oncoteam recommended adjuvant chemoradiotherapy all features strictly by Stupp protocol. (60 Gy dose on the gross tumor volume and 2-3 cm margin for the clinical target volume with parallel 75 mg/m2 TMZ. Four weeks after monotherapial phase patients had to recieve 6 cycles of TMZ first cycle with 150 mg/m2 up to 200 mg/m2). The irradiation was carried out by a conformal three dimensional planning system. Results - 59 patients with the median age of 63 (range 17-84) year. Our sample counted 34 male patients and 25 woman patients. 14 patients underwent gross total tumor resection while, 39 patients underwent partial resection and the rest from our sample 6 patients passed through biopsy. Statistical analysis showed a lengthier survival among males than females, with a median survival of 13 months for males and females, the OS of 26.209 for males, meanwhile 15.625 for females. However, the difference is not considerable (log-rank p=0.203). Our study found that the estimated survival of patients at least 50 years old is significantly shorter at a median survival of 12 months (log rank p=0.027) than that of patients below 50 years of age at a median survival of 23 months. The longest estimated median survival was calculated with patients of ECOG '0' condition (16 months). However, no significant difference was found in the estimated survival of patients of different ECOG conditions (log-rank p=0.146). Based on the extent of surgery, complete resection resulted in the longest average survival of 36.4 months, followed by 21.5 months among patients with biopsy, and 15.8 months among patients with partial resection. Different surgical procedures, however, did not result in significant differences in survival (log-rank p=0.059). The overal survival of patients who had complete resection confirmed by MRI compared with the overal survival of patients with residual tumor confirmed by MRI as well we can estimate that there is significant difference between these two groups (p=0,004). Conclusion - Despite complex and intense treatment, recurrence is inevitable and causes relatively rapid death. In our analysis complete resection, as defined from the neurosurgeon’s report and postoperative MRI, resulted in an independently significant improvement in OS. Our results are the evidences that the treatment of patients with glioblastoma multiforme in Hungary is at least on the same level as any other developed European countries.

Lege Artis Medicinae

[Analysis of short-term and long-term survival and causes of death in patients with systemic lupus erythematosus]

TARR Tünde, KISS Emese, SZEGEDI Gyula, ZEHER Margit

[INTRODUCTION - In systemic lupus erythematosus (SLE), both short-term and long-term survival rates have improved worldwide. We analysed retrospectively the short-term and long-term survival data and causes of death at a single center. These data were compared with previous survival data recorded at the same centre and published in international studies. PATIENTS AND METHOD - The data of 550 patients with SLE were analysed between 1970 and 2009. We examined the effect of clinical symptoms, age, severity and onset of the disease and the applied immunosuppressive treatment on survival, using the Kaplan-Meier method. RESULTS - Survival rates at 5, 10, 15 and 20 years after the diagnosis were 98%, 94%, 90% and 89%, respectively. Late onset, neuropsychiatric symptoms and severe SLE were found to be prognostic factors. Manifestations affecting other organs and the applied immunosuppressive therapy did not influence survival rates. During the study period, 57 out of the 550 patients (10.4%) died. The main causes of death were cardiovascular complications (50.9%), infections (21%), and malignancies (12.3%). CONCLUSIONS - Our results show that among patients with SLE, it is mostly longterm survival that has increased, owing to the close control of patients. The increase in cardiovascular mortality highlights the importance of regular screening.]

Lege Artis Medicinae

[OUR EXPERIENCE WITH BORTEZOMIB-BASED THERAPY OF MULTIPLE MYELOMA BASED ON THE FIRST 60 PATIENTS]

MIKALA Gábor, BÁTAI Árpád, CEGLÉDI Andrea, CSUKLY Zoltán, DOLGOS János, HALM Gabriella, JÁNOSI Judit, KAPÁS Balázs, LOVAS Nóra, LUEFF Sándor, PETŐ Mónika, REMÉNYI Péter, SIPOS Andrea, TÓTH Zsuzsanna

[INTRODUCTION - Bortezomib, a first-in-itsclass proteasome-inhibitor drug was registered in 2004 for the salvage treatment of relapsed and/or refractory multiple myeloma. We have been using this drug in our department for the treatment of myeloma patients since 2005. PATIENTS AND METHODS - In this retrospective study, treatment results (response rate, response duration, survival) as well as the complications and side effects were analysed based on 60 myeloma patients treated over a period of 18 months. The patients received at least one full cycle of non-first-line bortezomib-based (predominantly combinational) therapy. RESULTS - At least minimal laboratory and/or clinical response was observed in 47 of the 56 patients who could be analysed. Clinically meaningful (at least partial remission) response was seen in 41 of 56 patients. Immune-fixation negative complete remission was achieved in six patients. Median progression-free survival of our patient population was 13 months (10.8-14.8 months, n=49, adjusted for patients lost in the first 6 weeks and for those with less than 6 weeks of follow-up). As for overall survival, the median has not been reached, while treated patients had an 80.3% probability of survival at one year. CONCLUSIONS - Based on the treatment results of 60 myeloma patients, bortezomibbased therapy is clearly effective in relapsed and/or refractory myeloma.]

Lege Artis Medicinae

[Isolated anal form of Crohn’s disease with an extensive perianal septic complication]

DOBÓ István, JÓSVAY János

[INTRODUCTION - Perianal manifestations of Crohn’s disease are common. Treatment of advanced complications like strictures and incontinence may require a radical surgical intervention. We present a case of an extremely rare manifestation of Crohn’s disease. The disease localized exclusively to the anal canal for more than twenty years was complicated by an extensive perianal septic lesion. Besides our own surgical strategy, we discuss in detail other therapeutic options for perianal septic complications of Crohn’s disease. CASE REPORT - During 16 years of disease course the perianal process of the 34 year old female patient caused sphincter destruction and incontinence, and furthermore resulted in a chronic septic state by fistulous tracts involving the whole perineo-gluteal region. Following rectal extirpation, we performed a radical excision and a reconstructive operation using musculo- cutaneous/fascio-cutaneous advancement flaps. The final result of multiple operations of two years’ duration was functionally and aesthetically excellent. CONCLUSION - Fistulous tracts of perianal Crohn’s disease destructing widely their surroundings can only be cured by the radical excision of involved tissues. Extremely large consequent defects can also be covered with proper functional results by methods applying healthy tissues of good loadability i.e. musculocutaneous/ fascio-cutaneous advancement flaps.]